Bausch Health Companies Inc(BHC)
USD --+0.00%
Reward61Moderate
Risk47Moderate
📊75%Data
Thin 2% profit margin
BHC
+0.0 · +0.00%
USD · NYSE
Bausch Health Companies Inc | Healthcare
Deep Value
Market Cap:2.09Bn
ℹ️
Reward Rating
61
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
47
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BHC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $7.57.

What is Bausch Health Companies Inc?

operates as a diversified specialty pharmaceutical and medical device company.

BHC · Verdict

Solid reward · moderate risk

BHC stands out on valuation and volatility, but watch the balance sheet signal.

Based on 88% data coverage

BHC · Verdict

What’s working & what to watch

Strengths 3

  • Valuation85/100

    P/E 1.3× · PEG 0.01

  • Volatility80/100

    Top decile vs peers

  • Profitability70/100

    2% net margin · 44% ROE

Watchouts 1

  • Balance sheet23/100

    Interest covered 1.2×

Model-based scoring. For information only — not financial advice.

What is Bausch Health Companies Inc?

operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 2.09B, and a P/E ratio of 13.3x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap2.09B
P/E Ratio13.3095
Dividend YieldN/A
52 Week High8.69
52 Week Low4.41
Last AnnualDecember
IPO Date3/29/1994
IncorporatedUSA
Shares Outstanding373M
No. of Employees20,300
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNYSE
Beta0.398
CurrencyUSD